Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MDM4 | O15151 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22800271 | 0.84 | LMNA (0.31) | LMNA | |
| SCHEMBL23197727 | 0.81 | ALDH1A1 (0.31) | ALDH1A1ALOX12HTTGAAHIF1A | |
| SCHEMBL1645600 | 0.79 | NPC1 (0.47) | PTGS1ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL17903581 | 0.77 | ALOX15 (0.44) | LMNATRPA1PTGS1CACNA1CALDH1A1 | |
| SCHEMBL13086280 | 0.76 | LMNA (0.35) | LMNATRPA1PTGS1CACNA1CALDH1A1 | |
| SCHEMBL17561679 | 0.72 | TBXAS1 (0.40) | LMNA | |
| SCHEMBL19633832 | 0.72 | FABP4 (0.33) | — | |
| SCHEMBL24975129 | 0.72 | OGA (0.36) | — | |
| SCHEMBL26262656 | 0.69 | ACHE (0.32) | — | |
| SCHEMBL13086420 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242534-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20220389008-A1 | 4-QUINOLINONE ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-12-08 | — | — | US | disclosed |
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242534-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | CDK2, CDK5, CDK9 | LMNA 1562/4885TRPA1 2747/4885PTGS1 960/4885 |
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | CSF1R, CSF3R, MSR1 | LMNA 3953/4885TRPA1 4028/4885PTGS1 314/4885 |
| US-20220389008-A1 | 4-QUINOLINONE ANTIBACTERIAL COMPOUNDS | NQO2, NDUFS3, QARS1 | LMNA 2078/4885TRPA1 3281/4885PTGS1 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.